Medical News

RSS

AMICAS and Merge Healthcare sign definitive merger agreement

AMICAS, Inc. and Merge Healthcare Incorporated (Nasdaq: MRGE) today announced that they will enter into a definitive merger agreement pursuant to which Merge will acquire all of the outstanding shares of AMICAS for $6.05 per share in cash, or an aggregate of $248 million.

5 Mar 2010

Small health IT firms may be able to compete with GE-sized giants

Federal funding for electronic medical records will likely reshape the health IT industry, CNN reports. "There are an estimated 300 to 400 companies in the United States peddling [EMR] systems to the nation's hospitals, medical clinics and solo practitioners.

5 Mar 2010

Today's opinions and editorials

Some critics complain that the administration has slipped in its commitment to fiscal responsibility in health reform. These critics are mistaken. The president's plan represents an important step toward long-term fiscal sustainability (Peter Orszag and Nancy-Ann DeParle, 3/5).

5 Mar 2010

Advocates, opponents target about two dozen swing votes

"As President Obama pushes for a prompt up or down vote on his health initiative, lobbyists and activist groups on both sides of the issue have launched grass-roots and high-dollar advertising campaigns on the roughly two dozen members of Congress who may be the final swing votes on the controversial issue," The Los Angeles Times reports.

5 Mar 2010

YM Biosciences to raise $15M in registered direct offering of common stock

YM BioSciences Inc., today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit.

5 Mar 2010

MicroPhage seeks FDA clearance for MRSA/MSSA Blood Culture Test, submits clinical study data

MicroPhage announced that it has submitted human data from a pivotal clinical study of its ‘Microphage MRSA/MSSA Blood Culture Test’ to support a U.S. Food and Drug Administration (FDA) 510(k) premarket notification process. The first of MicroPhage’s instrument-free, rapid tests is based on the Company’s patented Bacteriophage Amplification platform technology. MicroPhage further announced that it has already begun OUS commercial shipments of the test.

5 Mar 2010

Study explores prognostic biomarkers in patients with lymph node-negative colorectal cancer

Tumor budding at the invasive tumor front of colorectal cancer is recognized as an independent prognostic factor significantly related to both lymph node and distant metastasis.

5 Mar 2010

Pregis announces expiration of Second Priority Senior Secured Floating Rate Notes due 2013 exchange offer

Pregis Corporation, a leading international manufacturer, marketer, and supplier of protective packaging products and specialty packaging solutions, today announced the expiration of its offer to exchange up to euro 125 million of its Second Priority Senior Secured Floating Rate Notes due 2013 issued in a private placement on October 5, 2009 for an equal principal amount of Second Priority Senior Secured Floating Rate Notes due 2013 that have been registered under the Securities Act of 1933, as amended.

5 Mar 2010

Moody's Investors Service upgrades Mylan's credit ratings

Mylan Inc. today reported that Moody's Investors Service upgraded the company's credit ratings, including the "Corporate Family Rating" to Ba3 from B1 and the senior secured bank rating to Ba2 from Ba3. Moody's also affirmed Mylan's SGL-1 Speculative Grade Liquidity Rating.

5 Mar 2010

Varian launches next generation dissolution apparatus

Varian, Inc. announced today the availability of its next generation dissolution apparatus designed for testing tablets, capsules and other dosage forms. The 708-DS supports a broad set of applications ranging from manual dissolution testing to automated, high-throughput analysis. It provides extensive flexibility to match the needs of individual laboratories, whether in research or testing. Integration with either the new Varian UV or LC Dissolution Systems will save time and reduce the potential for sample handling errors.

5 Mar 2010

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Saladax Biomedical, Inc. announced today the close of an $8.4 million Series C Preferred offering led by Excel Venture Management of Boston. Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors. The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.

5 Mar 2010

Medical identity theft: Nearly 1.5 million Americans have been victims

Medical identity theft is an alarming and often undetected offense affecting today’s consumers, according to a recent survey conducted by The Ponemon Institute and sponsored by ProtectMyID.com™, Experian’s multilayered identity theft detection, protection and fraud resolution product. According to the study, nearly 1.5 million Americans have been victims of medical identity theft. For many, the notion of identity theft is both upsetting and daunting, but few individuals realize the specific severity and potential repercussions of medical identity fraud.

5 Mar 2010

McKesson named "World's Most Admired" company and as one of 100 Best Corporate Citizens

McKesson Corporation, the nation’s largest healthcare services and information technology company, today was rated the "World's Most Admired" company in its industry in an annual survey conducted by FORTUNE magazine and the Hay Group. The company was also named one of the 100 Best Corporate Citizens by Corporate Responsibility Magazine.

5 Mar 2010

'Had Sex': Different perceptions

When people say they "had sex," what transpired is anyone's guess. A new study from the Kinsey Institute at Indiana University found that no uniform consensus existed when a representative sample of 18- to 96-year-olds was asked what the term meant to them.

5 Mar 2010

Liver transplantation specialists form guidelines for allocation of organs for patients with HCC

Liver transplantation specialists recently convened to address U.S. guidelines for allocation of organs for patients with hepatocellular carcinoma (HCC, liver cancer). Representatives from more than 130 U.S. transplant centers were invited to the conference and participants included 180 leaders in liver transplantation (LT) from the 50 most active centers.

5 Mar 2010

NanoViricides files Universal Form S-3 Shelf Registration with SEC

NanoViricides, Inc., reports that it has filed a “Universal Form S-3 Shelf Registration” with the Securities and Exchange Commission for the sale from time to time of up to $40 million of its securities. The Company recently became eligible to file a shelf registration to register its securities.

5 Mar 2010

Johnson & Johnson Consumer to introduce CYTOMIMIC Technology at 68th AAD meeting

Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies, Inc., have discovered how to harness the power of bioelectricity to help improve skin rejuvenation. The new innovation, called CYTOMIMIC™ Technology, is a proprietary, patented technology that combines essential minerals to deliver biological levels of electric signals similar to the skin's natural bioelectricity.

5 Mar 2010

LEO Pharma gains access to Intomics’ biological data analysis expertises

Today, Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics’ unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma’s early drug discovery.

5 Mar 2010

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2009 and provided an update on its progress.

5 Mar 2010

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.

5 Mar 2010

Medical News

AMICAS and Merge Healthcare sign definitive merger agreement

Small health IT firms may be able to compete with GE-sized giants

Today's opinions and editorials

Advocates, opponents target about two dozen swing votes

YM Biosciences to raise $15M in registered direct offering of common stock

MicroPhage seeks FDA clearance for MRSA/MSSA Blood Culture Test, submits clinical study data

Study explores prognostic biomarkers in patients with lymph node-negative colorectal cancer

Pregis announces expiration of Second Priority Senior Secured Floating Rate Notes due 2013 exchange offer

Moody's Investors Service upgrades Mylan's credit ratings

Varian launches next generation dissolution apparatus

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Medical identity theft: Nearly 1.5 million Americans have been victims

McKesson named "World's Most Admired" company and as one of 100 Best Corporate Citizens

'Had Sex': Different perceptions

Liver transplantation specialists form guidelines for allocation of organs for patients with HCC

NanoViricides files Universal Form S-3 Shelf Registration with SEC

Johnson & Johnson Consumer to introduce CYTOMIMIC Technology at 68th AAD meeting

LEO Pharma gains access to Intomics’ biological data analysis expertises

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News